Cerebrovascular disease underpins vascular dementia (VaD), but structural and functional
changes to the cerebral vasculature contribute to disease pathology and cognitive decline in …

Background and Objectives: The US Food and Drug Administration (FDA) defines a
biomarker as a characteristic that is measured as an indicator of normal biological …

Introduction Mild cognitive impairment (MCI) is a prodromal stage to dementia, affecting up
to 20% of the aging population worldwide. Patients with MCI have an annual conversion rate …

Alzheimer's disease (AD) is the most common degenerative disorder in the elderly in
developed countries. Currently, growing evidence is pointing at endothelial dysfunction as a …

Several studies have shown that an abnormal vascular-immunity link could increase
Alzheimer's disease (AD) risk; however, the mechanism is unclear. CD31, also named …

Alzheimer's disease (AD), the most prevalent form of dementia, is expected to rise
dramatically in incidence due to the global population aging. Traditional diagnostic …

Background There is an urgent need for cost-effective, easy-to-measure biomarkers to
identify subjects who will develop Alzheimer's disease (AD), especially at the pre …

Alzheimer's disease and stroke share several known vascular risk factors. The
pathophysiology and whether one predisposes to the other is a topic of ongoing …

Neurodegenerative diseases (NDDs) are an increasing group of chronic and progressive
neurological disorders that ultimately lead to neuronal cell failure and death. Despite all …

Neurodegenerative diseases constitute a broad range of central nervous system disorders,
characterized by neuronal degeneration. Alzheimer's disease, Parkinson's disease …